The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.
May 5th 2024
Despite often presenting to the hospital with similar non-psychiatric conditions, patients with schizophrenia often experience a more difficult care process than those without.
Antipsychotic Injections for Schizophrenia Linked to Decline in Hospital Readmissions
January 31st 2024In a study comparing readmission rates for patients with schizophrenia or schizoaffective disorder on oral or long-acting injections, investigators found after 30 days the readmission rate was 8.3% among patients who received pills and 1.9% among patients who received injections.
Jacob Ballon, MD, MPH: Discusses Takeaways from Studying Long-Term Olanzapine and Samidorphan
January 17th 2024In an interview, Jacob Ballon, MD, MPH, discusses the significance of his team’s study which found olanzapine and samidorphan was well-tolerable for up to 4 years of treatment for schizophrenia and bipolar disorder treatment.
Mothers’ Mental Disorders Is Not Linked to Type 1 Diabetes in Offspring
December 4th 2023Mothers with mood disorders—either bipolar disorder, major depressive disorder— or schizophrenia/ schizoaffective disorder are not associated with their offspring’s risk for type 1 diabetes. Results suggest mothers with bipolar disorder tend to develop type 1 diabetes, but data is not clinically significant.
FDA Accepts Xanomeline-Trospium Drug Application for Schizophrenia Treatment
November 29th 2023The FDA will decide on the approval of xanomeline-trospium, a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, for the treatment of schizophrenia patients by September 2024.
Investigators Identify Risk Factors for Drug-Induced Parkinsonism for Schizophrenia Patients
Various psychiatric symptoms, including more severe negative symptoms, lower cognition status, and lower excited symptoms were significantly linked to drug-induced parkinsonism induction.
Long-Acting Injectables Reduce Disease Relapse in Schizophrenia
Patients treated with LAIAs had a lower risk of hospitalization for any cause, hospitalizations for psychiatric disorders, hospitalizations for schizophrenia, and incident suicide attempts compared to patients treated with oral antipsychotics.